2型糖尿病肾脏损伤的深度内型分型:从一元到多元
本综述指出2型糖尿病肾脏损伤具有高度异质性,传统白蛋白尿和eGFR无法完全刻画其多样性。整合临床动态、肾脏病理和多组学可定义生物学上不同的内型,并需系统评估心-肝-肾-视网膜-血管轴。新兴疗法需与内型病理生物学匹配,推动从统一治疗转向精准医学。
要点
- 传统白蛋白尿和eGFR不能捕捉非白蛋白尿进展、eGFR快速下降或白蛋白尿消退等不典型轨迹。
- 深度内型分型整合临床动态、肾活检、多组学和影像可识别免疫、炎症、纤维化等分子签名。
- 2型糖尿病肾损伤需系统评估心-肝-肾-视网膜-血管内型,新兴疗法应匹配疾病病理生物学。
核心结论
- 2型糖尿病肾脏损伤应从「一种疾病」转向「多条通路」框架,以精准医学替代统一治疗。
研究设计与样本
- 本文为迷你综述,论述整合肾活检、多组学、影像和多器官分析 refine 2型糖尿病内型的路径。
主要发现
- 转录组、蛋白组、代谢组和单细胞空间分析揭示自身免疫、炎症、纤维化和细胞损伤的分子签名,与预后和治疗反应相关。
- 肾脏损伤与心脏、肝脏功能障碍、视网膜病变、神经病变和血管疾病相交,需系统层面评估。
临床怎么用
- 临床应超越白蛋白尿和eGFR,结合临床动态、病理和多组学识别内型。
- 治疗选择需对齐2型糖尿病内型的疾病病理生物学,而非统一方案。
- 评估肾脏时需同步关注心、肝、视网膜和血管系统,实施系统级照护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Kidney damage in type 2 diabetes exemplifies a complex, multisystemic disorder with substantial heterogeneity in clinical trajectory, histopathology, and molecular drivers. Traditional clinical markers, albuminuria and glomerular filtration rate, fail to capture this diversity because many patients follow atypical trajectories such as nonalbuminuric progression, rapid estimated glomerular filtration rate decline, or regression of albuminuria. Deep endotyping approaches integrating clinical dynamics, renal histopathology, and multi-omics profiling can define biologically distinct endotypes. Transcriptomic, proteomic, metabolomic, and single-cell spatial analysis reveal molecular signatures of autoimmunity, inflammation, fibrosis, and cellular injury associated with variable prognosis and therapeutic response. This heterogeneity extends systemically, with diabetic kidney impairment intersecting with cardiac and hepatic dysfunction, retinopathy, neuropathy, and vascular disease. A holistic, system-level approach, evaluating cardio-liver-kidney-retinal-vascular endotypes in tandem, is therefore required both for translational science and for comprehensive patient care. Recently approved and emerging therapies modulate inflammation, oxidative stress, autoimmunity, and fibrosis, offering pleiotropic benefits that must be aligned with the disease pathobiology of type 2 diabetes endotypes. This approach underscores the need to transition from uniform treatment toward precision medicine. This mini review highlights how integration of kidney biopsy, omics, imaging, and multiorgan profiling can refine endotypes in type 2 diabetes, advancing personalized therapy. Shifting from a "one disease" model to a "many pathways" framework represents a necessary evolution in the management of kidney damage in type 2 diabetes.
引用
- Gesualdo L, Kretzler M, Pontrelli P, et al. Deep endotyping of kidney damage in type 2 diabetes: ex uno, plures. Kidney Int. 2026. PMID: 41765180. doi:10.1016/j.kint.2026.01.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。